HROW

AI Memo

Harrow

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

TYRVAYA integration after completed acquisition • 2027-03-31

Base target: $30 / p=50% prob

Biggest risk

Management said first-half revenue was lighter than expected. Demand may not convert to the net sales and profitability needed for guidance; TYRVAYA integration also consumes cash before its returns are established [#PR-EARNINGS-2026-08-17] [#8-K-2026-10-05].

Invalidation

Break below $20 or thesis failure.

What would change my mind?

VEVYE coverage, IHEEZO pricing and unit demand, and the newly acquired TYRVAYA portfolio could support the substantial second-half acceleration needed to meet reiterated guidance [#SEC-8K-2026-08-10] [#8-K-2026-10-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

$30

p=50%

Bull target

$36

p=25%

Bear target

$20

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

VEVYE access and IHEEZO economics
Second-half delivery against 2026 guidance
VEVYE coverage, IHEEZO pricing and unit demand, and the newly acquired TYRVAYA portfolio could support the substantial second-half acceleration needed to meet reiterated guidance [#SEC-8K-2026-08-10] [#8-K-2026-10-05].

BearKey bullets

IHEEZO lost pass-through reimbursement; better unit demand must translate into durable net pricing and margins [#SEC-8K-2026-08-10].
Independent analyst revisions, current cash and leverage following the acquisition, and direct small-cap ophthalmic valuation peers are not established by the packet.
Meeting reiterated 2026 guidance requires a sharp second-half revenue step-up after management called first-half revenue lighter than expected [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-17].

WatchKey bullets

TYRVAYA integration after completed acquisition

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $30 (p=50%)

Target spread vs base: +20% / -33%

Scenario probabilities

Bull Target: $36 (p=25%)Base Target: $30 (p=50%)Bear Target: $20 (p=25%)

Commentary

Company-source Q2 operating commentary is constructive, and the October filing confirms TYRVAYA closed rather than remaining a prospective closing catalyst [#SEC-8K-2026-08-10] [#8-K-2026-10-05]. The supplied news items concern August results; post-acquisition price reaction and verified analyst revisions are unavailable. Social, options, short-interest, employee and 30-day news-sentiment measurements are unavailable; the zero fields above are placeholders, not observed neutral readings. An August Form 4 records an option exercise and sale of the same 11,250 shares, not evidence of operating performance [#SEC-FORM4-2026-08-17].

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

VEVYE access and IHEEZO economics
Second-half delivery against 2026 guidance

Scenarios

Bull Target (Scenario probability)

$36 / p=25% prob

Base Target (Scenario probability)

$30 / p=50% prob

Bear Target (Scenario probability)

$20 / p=25% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
TYRVAYA integration after completed acquisition
Harrow completed the TYRVAYA asset acquisition on October 1 and paid $30 million in cash. Viatris retained Japanese commercialization rights; up to $70 million of additional payments depend on sales thresholds. Closing risk has passed, but commercial integration and returns on the cash outlay remain unproven [#8-K-2026-10-05].
Prob 60.00% • Move 9.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

VEVYE access and IHEEZO economics
2026-12-31
Harrow reported Q2 VEVYE revenue of $29.4 million, expanded formulary coverage effective August 1, and record IHEEZO unit demand despite losing pass-through reimbursement. The test is whether coverage and improved pricing convert demand into net revenue and margin, not just prescriptions or units [#SEC-8K-2026-08-10].
Prob 65% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

Second-half delivery against 2026 guidance
2027-03-31
Harrow reiterated $350 million–$365 million of 2026 revenue and $80 million–$100 million of adjusted EBITDA guidance after Q2 revenue of $70.7 million. Management described first-half revenue of approximately $115 million as lighter than expected, implying a demanding second-half revenue step-up if guidance is met [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-17].
Prob 55% • Move 14% • Priced-in 45%

Risks

IHEEZO lost pass-through reimbursement; better unit demand must translate into durable net pricing and margins [#SEC-8K-2026-08-10].
Independent analyst revisions, current cash and leverage following the acquisition, and direct small-cap ophthalmic valuation peers are not established by the packet.
Meeting reiterated 2026 guidance requires a sharp second-half revenue step-up after management called first-half revenue lighter than expected [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-17].
TYRVAYA integration and commercialization must justify the $30 million cash payment; further payments of up to $70 million are contingent on sales thresholds [#8-K-2026-10-05].

Peers

Symbol	Summary
AMGN	Broad biopharma sector benchmark, not a verified direct ophthalmic operating peer; its much larger scale limits valuation comparability.
REGN	Narrow product-market comparison only: Regeneron's filing identifies a U.S.-commercialized Harrow Lucentis biosimilar in its discussion of EYLEA competition. No Harrow economic exposure is disclosed, and REGN's scale makes it a weak valuation peer [#REL-6b076dcb-a206-42a2-9f95-d14ccfc1f8de]; source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

AMGN

Broad biopharma sector benchmark, not a verified direct ophthalmic operating peer; its much larger scale limits valuation comparability.

REGN

Narrow product-market comparison only: Regeneron's filing identifies a U.S.-commercialized Harrow Lucentis biosimilar in its discussion of EYLEA competition. No Harrow economic exposure is disclosed, and REGN's scale makes it a weak valuation peer [#REL-6b076dcb-a206-42a2-9f95-d14ccfc1f8de]; source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm.